PURPOSE: To assess the prognostic and predictive value of circulating tumor cells (CTCs) in metastatic colorectal cancer (mCRC) irrespective of detection level. MATERIALS AND METHODS: We evaluated the prognostic and predictive significance of CTC count at baseline and under treatment in 119 mCRC subjects and compared the standard cutoff (≥3 CTCs/7.5 mL to ≥1 CTCs/7.5 mL). RESULTS: An overall comparison was made between patients with 0, 1-2 and ≥3 CTC (median PFS 8, 4 and 5 months, respectively). Two poor prognostic groups were found, including patients with ≥1 CTCs before and during treatment and patients with 0 CTC at baseline who converted to ≥1 CTCs (p = 0.014). CONCLUSIONS: The presence of at least 1 CTC at baseline count is predictive for poor prognosis in mCRC patients. Patients with 1-2 CTC should be switched from the favorable prognostic group--conventionally defined by the presence of <3 CTC--to the unfavorable, deserving a more careful monitoring.
PURPOSE: To assess the prognostic and predictive value of circulating tumor cells (CTCs) in metastatic colorectal cancer (mCRC) irrespective of detection level. MATERIALS AND METHODS: We evaluated the prognostic and predictive significance of CTC count at baseline and under treatment in 119 mCRC subjects and compared the standard cutoff (≥3 CTCs/7.5 mL to ≥1 CTCs/7.5 mL). RESULTS: An overall comparison was made between patients with 0, 1-2 and ≥3 CTC (median PFS 8, 4 and 5 months, respectively). Two poor prognostic groups were found, including patients with ≥1 CTCs before and during treatment and patients with 0 CTC at baseline who converted to ≥1 CTCs (p = 0.014). CONCLUSIONS: The presence of at least 1 CTC at baseline count is predictive for poor prognosis in mCRC patients. Patients with 1-2 CTC should be switched from the favorable prognostic group--conventionally defined by the presence of <3 CTC--to the unfavorable, deserving a more careful monitoring.
Authors: F C Bidard; F R Ferrand; F Huguet; P Hammel; C Louvet; D Malka; V Boige; M Ducreux; T Andre; A de Gramont; P Mariani; J Y Pierga Journal: Crit Rev Oncol Hematol Date: 2011-06-15 Impact factor: 6.312
Authors: W Jeffrey Allard; Jeri Matera; M Craig Miller; Madeline Repollet; Mark C Connelly; Chandra Rao; Arjan G J Tibbe; Jonathan W Uhr; Leon W M M Terstappen Journal: Clin Cancer Res Date: 2004-10-15 Impact factor: 12.531
Authors: S J Cohen; C J A Punt; N Iannotti; B H Saidman; K D Sabbath; N Y Gabrail; J Picus; M A Morse; E Mitchell; M C Miller; G V Doyle; H Tissing; L W M M Terstappen; N J Meropol Journal: Ann Oncol Date: 2009-03-12 Impact factor: 32.976
Authors: Massimo Cristofanilli; G Thomas Budd; Matthew J Ellis; Alison Stopeck; Jeri Matera; M Craig Miller; James M Reuben; Gerald V Doyle; W Jeffrey Allard; Leon W M M Terstappen; Daniel F Hayes Journal: N Engl J Med Date: 2004-08-19 Impact factor: 91.245
Authors: Steven J Cohen; Cornelis J A Punt; Nicholas Iannotti; Bruce H Saidman; Kert D Sabbath; Nashat Y Gabrail; Joel Picus; Michael Morse; Edith Mitchell; M Craig Miller; Gerald V Doyle; Henk Tissing; Leon W M M Terstappen; Neal J Meropol Journal: J Clin Oncol Date: 2008-07-01 Impact factor: 44.544
Authors: Johann S de Bono; Howard I Scher; R Bruce Montgomery; Christopher Parker; M Craig Miller; Henk Tissing; Gerald V Doyle; Leon W W M Terstappen; Kenneth J Pienta; Derek Raghavan Journal: Clin Cancer Res Date: 2008-10-01 Impact factor: 12.531
Authors: David R Parkinson; Nicholas Dracopoli; Brenda Gumbs Petty; Carolyn Compton; Massimo Cristofanilli; Albert Deisseroth; Daniel F Hayes; Gordon Kapke; Prasanna Kumar; Jerry Sh Lee; Minetta C Liu; Robert McCormack; Stanislaw Mikulski; Larry Nagahara; Klaus Pantel; Sonia Pearson-White; Elizabeth A Punnoose; Lori T Roadcap; Andrew E Schade; Howard I Scher; Caroline C Sigman; Gary J Kelloff Journal: J Transl Med Date: 2012-07-02 Impact factor: 5.531
Authors: Z S Lalmahomed; B Mostert; W Onstenk; J Kraan; N Ayez; J W Gratama; D Grünhagen; C Verhoef; S Sleijfer Journal: Br J Cancer Date: 2015-01-06 Impact factor: 7.640
Authors: Lars Thomas Seeberg; Cathrine Brunborg; Anne Waage; Harald Hugenschmidt; Anne Renolen; Ingunn Stav; Bjørn A Bjørnbeth; Elin Borgen; Bjørn Naume; Kristoffer W Brudvik; Gro Wiedswang Journal: Ann Surg Oncol Date: 2017-03-03 Impact factor: 5.344
Authors: Hanna Huebner; Peter A Fasching; Walter Gumbrecht; Sebastian Jud; Claudia Rauh; Mark Matzas; Peter Paulicka; Katja Friedrich; Michael P Lux; Bernhard Volz; Paul Gass; Lothar Häberle; Franziska Meier-Stiegen; Andreas Hartkopf; Hans Neubauer; Katrin Almstedt; Matthias W Beckmann; Tanja N Fehm; Matthias Ruebner Journal: BMC Cancer Date: 2018-02-20 Impact factor: 4.430
Authors: James W T Toh; Stephanie H Lim; Scott MacKenzie; Paul de Souza; Les Bokey; Pierre Chapuis; Kevin J Spring Journal: Cells Date: 2020-02-12 Impact factor: 6.600